NCT01407575View on ClinicalTrials.gov

Buprenorphine for Treatment Resistant Depression

PHASE3CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
DepressionDepressive DisorderDepressive Disorder, Major
Interventions
DRUG

Buprenorphine

low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)

DRUG

Placebo

matched placebo

Trial Locations (1)

15213

Western Psychiatric Institute and Clinic, University of Pittsburgh, Pittsburgh

All Listed Sponsors
collaborator

National Alliance for Research on Schizophrenia and Depression

OTHER

lead

University of Pittsburgh

OTHER

NCT01407575 - Buprenorphine for Treatment Resistant Depression | Biotech Hunter | Biotech Hunter